Lysophospholipids and their G protein-coupled receptors in atherosclerosis

Frontiers in Bioscience - Landmark

Volumn 21, Issue 1, 2016, Pages 70-88

  Li, Ya Feng ^a,b   Li, Rong Shan ^c   Samuel, Sonia B ^a   Cueto, Ramon ^a   Li, Xin Yuan ^a   Wang, Hong ^a   Yang, Xiao Feng ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SHANXI MEDICAL UNIVERSITY   (China)

^c SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

Atherosclerosis; G protein coupled receptors; Lysophospholipids; Review; Vascular inflammation

Indexed keywords

G PROTEIN COUPLED RECEPTOR; LYSOPHOSPHOLIPID;

ATHEROSCLEROSIS; BIOSYNTHESIS; HUMAN; LYMPHOCYTE; MACROPHAGE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR SMOOTH MUSCLE;

ATHEROSCLEROSIS; HUMANS; LYMPHOCYTES; LYSOPHOSPHOLIPIDS; MACROPHAGES; MUSCLE, SMOOTH, VASCULAR; RECEPTORS, G-PROTEIN-COUPLED;

EID: 85016163268     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4377     Document Type: Review

References (68)

1. E. J. Goetzl, M. Graeler, M. C. Huang and G. Shankar: Lysophospholipid growth factors and their G protein-coupled receptors in immunity, coronary artery disease, and cancer. Scientific World Journal, 2, 324-38 (2002) DOI: 10.1100/tsw.2002.124
2. M. C. Huang, M. Graeler, G. Shankar, J. Spencer and E. J. Goetzl: Lysophospholipid mediators of immunity and neoplasia. Biochim Biophys Acta, 1582(1-3), 161-7 (2002) DOI: 10.1016/S1388-1981(02)00151-8
3. J. W. Lee, S. Nishiumi, M. Yoshida, E. Fukusaki and T. Bamba: Simultaneous profiling of polar lipids by supercritical fluid chromatography/ tandem mass spectrometry with methylation. J Chromatogr A, 1279, 98-107 (2013) DOI: 10.1016/j.chroma.2013.01.020
4. D. Meyer zu Heringdorf and K. H. Jakobs: Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism. Biochim Biophys Acta, 1768(4), 923-40 (2007) DOI: 10.1.016/j.bbamem.2006.0.9.0.26
5. A. Grzelczyk and E. Gendaszewska- Darmach: Novel bioactive glycerol-based lysophospholipids: new data - new insight into their function. Biochimie, 95(4), 667-79 (2013) DOI: 10.1.016/j.biochi.2012.1.0.0.09
6. A. M. P. von Bayern, R. J. P. Heathcote, C. Rutz and A. Kacelnik: The role of experience in problem solving and innovative tool use in crows. Current Biology, 19(22), 1965-1968 (2009) DOI: 10.1.016/j.cub.2009.1.0.0.37
7. N. Fukushima, I. Ishii, J. J. Contos, J. A. Weiner and J. Chun: Lysophospholipid receptors. Annu Rev Pharmacol Toxicol, 41, 507-34 (2001) DOI: 10.1146/annurev.pharmtox.41.1.507
8. J. D. Saba: Lysophospholipids in development: Miles apart and edging in. J Cell Biochem, 92(5), 967-92 (2004) DOI: 10.1.002/jcb.20128
9. C. K. Means and J. H. Brown: Sphingosine- 1-phosphate receptor signalling in the heart. Cardiovasc Res, 82(2), 193-200 (2009) DOI: 10.1.093/cvr/cvp086
10. A. Schober and W. Siess: Lysophosphatidic acid in atherosclerotic diseases. Br J Pharmacol, 167(3), 465-82 (2012) DOI: 10.1.111/j.1476-5381.2.012.0.2021.x
11. S. Willier, E. Butt and T. G. Grunewald: Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays. Biol Cell, 105(8), 317-33 (2013) DOI: 10.1.111/boc.201300011
12. B. Anliker and J. Chun: Lysophospholipid G protein-coupled receptors. J Biol Chem, 279(20), 20555-8 (2004) DOI: 10.1.074/jbc.R400013200
13. T. I. Torkhovskaya, O. M. Ipatova, T. S. Zakharova, M. M. Kochetova and E. M. Khalilov: Lysophospholipid receptors in cell signaling. Biochemistry (Mosc), 72(2), 125-31 (2007) DOI: 10.1134/S0006297907020010
14. S. Y. Xiang, S. S. Dusaban and J. H. Brown: Lysophospholipid receptor activation of RhoA and lipid signaling pathways. Biochim Biophys Acta, 1831(1), 213-22 (2013) DOI: 10.1.016/j.bbalip.2012.0.9.0.04
15. J. H. Hecht, J. A. Weiner, S. R. Post and J. Chun: Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J Cell Biol, 135(4), 1071-83 (1996) DOI: 10.1083/jcb.135.4.1071
16. A. P. Davenport, S. P. Alexander, J. L. Sharman, A. J. Pawson, H. E. Benson, A. E. Monaghan, W. C. Liew, C. P. Mpamhanga, T. I. Bonner, R. R. Neubig, J. P. Pin, M. Spedding and A. J. Harmar: International Union of Basic and Clinical Pharmacology. LXXXVIII. G proteincoupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev, 65(3), 967-86 (2013) DOI: 10.1.124/pr.112.0.07179
17. S. M. Foord, T. I. Bonner, R. R. Neubig, E. M. Rosser, J. P. Pin, A. P. Davenport, M. Spedding and A. J. Harmar: International Union of Pharmacology. XLVI. G proteincoupled receptor list. Pharmacol Rev, 57(2), 279-88 (2005) DOI: 10.1.124/pr.57.2.5.
18. J. Chun, E. J. Goetzl, T. Hla, Y. Igarashi, K. R. Lynch, W. Moolenaar, S. Pyne and G. Tigyi: International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev, 54(2), 265-9 (2002) DOI: 10.1124/pr.54.2.265
19. G. Schmitz and K. Ruebsaamen: Metabolism and atherogenic disease association of lysophosphatidylcholine. Atherosclerosis, 208(1), 10-8 (2010) DOI: 10.1.016/j.atherosclerosis.2009.0.5.0.29
20. J. Chun, T. Hla, K. R. Lynch, S. Spiegel and W. H. Moolenaar: International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol Rev, 62(4), 579-87 (2010) DOI: 10.1.124/pr.110.0.03111
21. N. Fukushima, Y. Kimura and J. Chun: A single receptor encoded by vzg-1/lpA1/edg-2 couples to G proteins and mediates multiple cellular responses to lysophosphatidic acid. Proc Natl Acad Sci U S A, 95(11), 6151-6 (1998) DOI: 10.1073/pnas.95.11.6151
22. N. A. Balenga, E. Aflaki, J. Kargl, W. Platzer, R. Schroder, S. Blattermann, E. Kostenis, A. J. Brown, A. Heinemann and M. Waldhoer: GPR55 regulates cannabinoid 2 receptormediated responses in human neutrophils. Cell Res, 21(10), 1452-69 (2011) DOI: 10.1.038/cr.2011.6.0
23. Y. Takuwa, Y. Okamoto, K. Yoshioka and N. Takuwa: Sphingosine-1-phosphate signaling and biological activities in the cardiovascular system. Biochim Biophys Acta, 1781(9), 483-8 (2008) DOI: 10.1.016/j.bbalip.2008.0.4.0.03
24. W. H. Moolenaar: Bioactive lysophospholipids and their G protein-coupled receptors. Exp Cell Res, 253(1), 230-8 (1999) DOI: 10.1.006/excr.1999.4.702
25. R. Rivera and J. Chun: Biological effects of lysophospholipids. Rev Physiol Biochem Pharmacol, 160, 25-46 (2008) DOI: 10.1.007/112-0507
26. W. H. Moolenaar and T. Hla: SnapShot: Bioactive lysophospholipids. Cell, 148(1-2), 378-378 e2 (2012) DOI: 10.1.016/j.cell.2012.0.1.0.13
27. M. Z. Cui: Lysophosphatidic acid effects on atherosclerosis and thrombosis. Clin Lipidol, 6(4), 413-426 (2011) DOI: 10.2.217/clp.11.3.8
28. F. Wang, Y. Okamoto, I. Inoki, K. Yoshioka, W. Du, X. Qi, N. Takuwa, K. Gonda, Y. Yamamoto, R. Ohkawa, T. Nishiuchi, N. Sugimoto, Y. Yatomi, K. Mitsumori, M. Asano, M. Kinoshita and Y. Takuwa: Sphingosine-1-phosphate receptor-2 deficiency leads to inhibition of macrophage proinflammatory activities and atherosclerosis in apoE-deficient mice. J Clin Invest, 120(11), 3979-95 (2010) DOI: 10.1.172/JCI42315
29. E. Ninio: Phospholipid mediators in the vessel wall: involvement in atherosclerosis. Curr Opin Clin Nutr Metab Care, 8(2), 123-31 (2005) DOI: 10.1097/00075197-200503000-00004
30. C. I. Lin, C. N. Chen, J. H. Chen and H. Lee: Lysophospholipids increase IL-8 and MCP-1 expressions in human umbilical cord vein endothelial cells through an IL-1-dependent mechanism. J Cell Biochem, 99(4), 1216-32 (2006) DOI: 10.1.002/jcb.20963
31. C. Gustin, E. Delaive, M. Dieu, D. Calay and M. Raes: Upregulation of pentraxin-3 in human endothelial cells after lysophosphatidic acid exposure. Arterioscler Thromb Vasc Biol, 28(3), 491-7 (2008) DOI: 10.1.161/ATVBAHA.107.1.58642
32. J. S. Alexander, W. F. Patton, B. W. Christman, L. L. Cuiper and F. R. Haselton: Plateletderived lysophosphatidic acid decreases endothelial permeability in vitro. Am J Physiol, 274(1 Pt 2), H115-22 (1998)
33. G. P. van Nieuw Amerongen, M. A. Vermeer and V. W. van Hinsbergh: Role of RhoA and Rho kinase in lysophosphatidic acid-induced endothelial barrier dysfunction. Arterioscler Thromb Vasc Biol, 20(12), E127-33 (2000) DOI: 10.1161/01.ATV.20.12.e127
34. K. Hayashi, M. Takahashi, W. Nishida, K. Yoshida, Y. Ohkawa, A. Kitabatake, J. Aoki, H. Arai and K. Sobue: Phenotypic modulation of vascular smooth muscle cells induced by unsaturated lysophosphatidic acids. Circ Res, 89(3), 251-8 (2001) DOI: 10.1161/hh1501.094265
35. F. Hao, M. Tan, D. D. Wu, X. Xu and M. Z. Cui: LPA induces IL-6 secretion from aortic smooth muscle cells via an LPA1-regulated, PKC-dependent, and p38alpha-mediated pathway. Am J Physiol Heart Circ Physiol, 298(3), H974-83 (2010) DOI: 10.1.152/ajpheart.00895.2.009
36. F. Pietruck, S. Busch, S. Virchow, N. Brockmeyer and W. Siffert: Signalling properties of lysophosphatidic acid in primary human skin fibroblasts: role of pertussis toxin-sensitive GTP-binding proteins. Naunyn Schmiedebergs Arch Pharmacol, 355(1), 1-7 (1997) DOI: 10.1007/PL00004906
37. S. Sartore, A. Chiavegato, E. Faggin, R. Franch, M. Puato, S. Ausoni and P. Pauletto: Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant. Circ Res, 89(12), 1111-21 (2001) DOI: 10.1161/hh2401.100844
38. C. L. Chang, H. Y. Hsu, H. Y. Lin, W. Chiang and H. Lee: Lysophosphatidic acid-induced oxidized low-density lipoprotein uptake is class A scavenger receptor-dependent in macrophages. Prostaglandins Other Lipid Mediat, 87(1-4), 20-5 (2008) DOI: 10.1.016/j.prostaglandins.2008.0.5.0.02
39. R. Chen, J. Roman, J. Guo, E. West, J. McDyer, M. A. Williams and S. N. Georas: Lysophosphatidic acid modulates the activation of human monocyte-derived dendritic cells. Stem Cells Dev, 15(6), 797-804 (2006) DOI: 10.1.089/scd.2006.1.5.7.97
40. Y. Zheng, J. K. Voice, Y. Kong and E. J. Goetzl: Altered expression and functional profile of lysophosphatidic acid receptors in mitogenactivated human blood T lymphocytes. FASEB J, 14(15), 2387-9 (2000) DOI: 10.1.096/fj.00-0492fje
41. Y. C. Yung, N. C. Stoddard and J. Chun: LPA receptor signaling: pharmacology, physiology, and pathophysiology. J Lipid Res, 55(7), 1192-1214 (2014) DOI: 10.1.194/jlr.R046458
42. L. V. Yang, C. G. Radu, L. Wang, M. Riedinger and O. N. Witte: Gi-independent macrophage chemotaxis to lysophosphatidylcholine via the immunoregulatory GPCR G2A. Blood, 105(3), 1127-34 (2005) DOI: 10.1.182/blood-2004-05-1916
43. J. Qiao, F. Huang, R. P. Naikawadi, K. S. Kim, T. Said and H. Lum: Lysophosphatidylcholine impairs endothelial barrier function through the G protein-coupled receptor GPR4. Am J Physiol Lung Cell Mol Physiol, 291(1), L91-101 (2006) DOI: 10.1.152/ajplung.00508.2.005
44. T. Matsumoto, T. Kobayashi and K. Kamata: Role of lysophosphatidylcholine (LPC) in atherosclerosis. Curr Med Chem, 14(30), 3209-20 (2007) DOI: 10.2174/092986707782793899
45. N. Kume, M. I. Cybulsky and M. A. Gimbrone, Jr.: Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest, 90(3), 1138-44 (1992) DOI: 10.1.172/JCI115932
46. N. Aiyar, J. Disa, Z. Ao, H. Ju, S. Nerurkar, R. N. Willette, C. H. Macphee, D. G. Johns and S. A. Douglas: Lysophosphatidylcholine induces inflammatory activation of human coronary artery smooth muscle cells. Mol Cell Biochem, 295(1-2), 113-20 (2007) DOI: 10.1.007/s11010-006-9280-x
47. N. Zurgil, E. Afrimzon, Y. Shafran, O. Shovman, B. Gilburd, H. Brikman, Y. Shoenfeld and M. Deutsch: Lymphocyte resistance to lysophosphatidylcholine mediated apoptosis in atherosclerosis. Atherosclerosis, 190(1), 73-83 (2007) DOI: 10.1.016/j.atherosclerosis.2006.0.2.0.13
48. K. E. Olofsson, L. Andersson, J. Nilsson and H. Bjorkbacka: Nanomolar concentrations of lysophosphatidylcholine recruit monocytes and induce pro-inflammatory cytokine production in macrophages. Biochem Biophys Res Commun, 370(2), 348-52 (2008) DOI: 10.1.016/j.bbrc.2008.0.3.0.87
49. H. Domeij, X. Hua, J. Su, A. Backlund, Z. Yan, A. G. Frostegard, J. Z. Haeggstrom, T. Modeer and J. Frostegard: Annexin A5 inhibits atherogenic and pro-inflammatory effects of lysophosphatidylcholine. Prostaglandins Other Lipid Mediat, 106, 72-8 (2013) DOI: 10.1016/j.prostaglandins.2013.01.004
50. B. Engelmann, S. Zieseniss, K. Brand, S. Page, A. Lentschat, A. J. Ulmer and E. Gerlach: Tissue factor expression of human monocytes is suppressed by lysophosphatidylcholine. Arterioscler Thromb Vasc Biol, 19(1), 47-53 (1999) DOI: 10.1161/01.ATV.19.1.47
51. J. Beltowski: Lysophosphatidylinositol-GPR55 Signaling in the Regulation of Metabolism and Cardiometabolic Disorders. Adipobiology, 23-31 (2013)
52. M. Bot, P. P. Van Veldhoven, S. C. de Jager, J. Johnson, N. Nijstad, P. J. Van Santbrink, M. M. Westra, G. Van Der Hoeven, M. J. Gijbels, C. Muller-Tidow, G. Varga, U. J. Tietge, J. Kuiper, T. J. Van Berkel, J. R. Nofer, I. Bot and E. A. Biessen: Hematopoietic sphingosine 1-phosphate lyase deficiency decreases atherosclerotic lesion development in LDLreceptor deficient mice. PLoS One, 8(5), e63360 (2013) DOI: 10.1371/journal.pone.0063360
53. K. Tamama and F. Okajima: Sphingosine 1-phosphate signaling in atherosclerosis and vascular biology. Curr Opin Lipidol, 13(5), 489-95 (2002) DOI: 10.1097/00041433-200210000-00004
54. F. Poti, M. Simoni and J. R. Nofer: Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1- phosphate (S1P). Cardiovasc Res, 103(3), 395-404 (2014) DOI: 10.1.093/cvr/cvu136
55. T. Kimura, T. Watanabe, K. Sato, J. Kon, H. Tomura, K. Tamama, A. Kuwabara, T. Kanda, I. Kobayashi, H. Ohta, M. Ui and F. Okajima: Sphingosine 1-phosphate stimulates proliferation and migration of human endothelial cells possibly through the lipid receptors, Edg-1 and Edg-3. Biochem J, 348 Pt 1, 71-6 (2000) DOI: 10.1042/0264-6021:3480071
56. P. Xia, J. R. Gamble, K. A. Rye, L. Wang, C. S. Hii, P. Cockerill, Y. Khew-Goodall, A. G. Bert, P. J. Barter and M. A. Vadas: Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. Proc Natl Acad Sci U S A, 95(24), 14196-201 (1998) DOI: 10.1073/pnas.95.24.14196
57. F. Okajima: Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator? Biochim Biophys Acta, 1582(1-3), 132-7 (2002) DOI: 10.1016/S1388-1981(02)00147-6
58. S. Pyne and N. J. Pyne: Sphingosine 1-phosphate signalling in mammalian cells. Biochem J, 349(Pt 2), 385-402 (2000) DOI: 10.1042/0264-6021:3490385
59. H. Y. Lee, S. Y. Lee, S. D. Kim, J. W. Shim, H. J. Kim, Y. S. Jung, J. Y. Kwon, S. H. Baek, J. Chung and Y. S. Bae: Sphingosylphosphorylcholine stimulates CCL2 production from human umbilical vein endothelial cells. J Immunol, 186(7), 4347-53 (2011) DOI: 10.4.049/jimmunol.1002068
60. E. S. Jeon, H. J. Moon, M. J. Lee, H. Y. Song, Y. M. Kim, Y. C. Bae, J. S. Jung and J. H. Kim: Sphingosylphosphorylcholine induces differentiation of human mesenchymal stem cells into smooth-muscle-like cells through a TGF-beta-dependent mechanism. J Cell Sci, 119(Pt 23), 4994-5005 (2006) DOI: 10.1.242/jcs.03281
61. S. S. Smyth, H. Y. Cheng, S. Miriyala, M. Panchatcharam and A. J. Morris: Roles of lysophosphatidic acid in cardiovascular physiology and disease. Biochim Biophys Acta, 1781(9), 563-70 (2008) DOI: 10.1.016/j.bbalip.2008.0.5.0.08
62. J. S. Karliner: Lysophospholipids and the cardiovascular system. Biochim Biophys Acta, 1582(1-3), 216-21 (2002) DOI: 10.1016/S1388-1981(02)00174-9
63. M. R. Alexander and G. K. Owens: Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease. Annu Rev Physiol, 74, 13-40 (2012) DOI: 10.1146/annurev-physiol-012110- 142315
64. D. Gomez and G. K. Owens: Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc Res, 95(2), 156-64 (2012) DOI: 10.1.093/cvr/cvs115
65. M. Z. Cui, E. Laag, L. Sun, M. Tan, G. Zhao and X. Xu: Lysophosphatidic acid induces early growth response gene 1 expression in vascular smooth muscle cells: CRE and SRE mediate the transcription. Arterioscler Thromb Vasc Biol, 26(5), 1029-35 (2006) DOI: 10.1.161/01.ATV.0000214980.9.0567.b5
66. T. Iyoda, F. Zhang, L. Sun, F. Hao, C. Schmitz- Peiffer, X. Xu and M. Z. Cui: Lysophosphatidic acid induces early growth response-1 (Egr-1) protein expression via protein kinase Cdeltaregulated extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) activation in vascular smooth muscle cells. J Biol Chem, 287(27), 22635-42 (2012) DOI: 10.1.074/jbc.M111.3.35695
67. J. Shi, Y. Dong, M. Z. Cui and X. Xu: Lysophosphatidic acid induces increased BACE1 expression and Abeta formation. Biochim Biophys Acta, 1832(1), 29-38 (2013) DOI: 10.1.016/j.bbadis.2012.0.9.0.10
68. M. Tan, F. Hao, X. Xu, G. M. Chisolm and M. Z. Cui: Lysophosphatidylcholine activates a novel PKD2-mediated signaling pathway that controls monocyte migration. Arterioscler Thromb Vasc Biol, 29(9), 1376-82 (2009) DOI: 10.1.161/ATVBAHA.109.1.91585